Nippon Shinyaku took up its option on U.S. rights to AB2 Bio’s interleukin-18 neutralizing drug tadekinig alfa, triggering a $30 million milestone and setting up further development and commercialization payments totaling up to $650 million. The licensed use is tied to primary pediatric IL-18-driven hyperinflammation, an ultra-rare inherited disorder that can progress to multi-organ failure without treatment. The deal reinforces how specialty biotechs can extend value through regional licensing while maintaining focus on targeted development paths for rare immune-driven diseases. For Nippon Shinyaku, the agreement expands its portfolio of inflammatory pathway assets with a clear ultra-orphan rationale. The next industry checkpoint will be clinical progression under the U.S. rights framework—especially evidence of durable control of hyperinflammatory cascades and manageable safety for pediatric use.